Pay in 4 interest-free payments of $7.38 Learn more
Ships within 48 hours · Estimated delivery Aug 29 - Sep 3
Once-weekly cagrilintide for weight management in people with overweight and obesity: a multicentre, randomised, double-blind, placebo-controlled and active-controlled, dose-finding phase 2 trial. Lancet 398(10317):21602172
Galuppo et al., 2013), and reduced motor impairments (Galuppo et al., 2013)
The molecule retains the complete 70-amino-acid native IGF-1 sequence with two structural modifications a 13-amino-acid N-terminal extension (the Long designation) and an arginine-for-glutamic-acid substitution at position 3 (the R3 designation) which together reduce binding affinity to circulating IGF binding proteins (IGFBPs) by approximately 600-fold while preserving full agonist activity at the IGF-1 receptor
doi: 10.1046/j.1365-2125.2001.01305.x Watkins PB, Kaplowitz N, Slattery JT, et al
The AWARD- 6 trial revealed that dulaglutide was not inferior to liraglutide in terms of lowering HbA1c
US$ 25.00
US$ 27.39
US$ 24.30
US$ 20.05
US$ 29.28
US$ 29.16
US$ 21.10
